Zacks Investment Research cut shares of Bayer AG (NASDAQ:BAYRY) from a hold rating to a sell rating in a report issued on Tuesday.
According to Zacks, “Bayer’s shares have underperformed the Large Cap Pharma industry year to date. The company has been facing generic threats for many of its products. Moreover, continued weak performance of key drugs could impact the company’s top line. In addition, we are concerned about Bayer’s dependence on the Pharmaceuticals segment for growth. Below-par sales at this segment may weigh heavily on the stock. Its history of pipeline setbacks remains a headwind as well. Nevertheless, Bayer’s Life Science businesses continue to perform well, particularly Pharmaceuticals. Newly launched products in the segment should continue to drive top-line growth. Bayer has made several acquisitions and entered into a number of deals to boost its portfolio in the past few quarters. In its attempt to create a global leader in agriculture, Bayer is looking to acquire Monsanto in a deal worth about $66 billion.”
Separately, Jefferies Group upgraded shares of Bayer AG from a hold rating to a buy rating in a report on Monday.
Bayer AG (NASDAQ:BAYRY) opened at 103.12 on Tuesday. Bayer AG has a 52-week low of $91.53 and a 52-week high of $128.69. The firm has a 50-day moving average of $0.00 and a 200 day moving average of $0.00.
About Bayer AG
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures.